BioCentury
ARTICLE | Clinical News

Reolysin: Completed Phase II enrollment

September 15, 2014 7:00 AM UTC

Oncolytics said the Gynecologic Oncology Group (GOG) completed enrollment of about 150 patients in an open-label, U.S. Phase II trial comparing IV Reolysin on days 1-5 of 28-day cycles plus paclitaxel on days 1, 8 and 15 of 28-day cycles vs. paclitaxel alone. The trial is sponsored by the NCI through a clinical trials agreement between NCI's Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnostic, NCI and Oncolytics. Oncolytics is providing clinical supplies of Reolysin for the trial. ...